Navigation Links
Next Inning Technology Research Identifies Winning Option Writing Strategies on Undervalued Stocks
Date:3/11/2009

PRINCETON, N.J., March 11 /PRNewswire/ -- Next Inning Technology Research (http://www.nextinning.com), a subscription service focused on semiconductor and technology stocks, announced it has published a series of reports updating outlooks for Analog Devices (NYSE: ADI), Maxim Integrated Products (Nasdaq: MXIM), Pfizer (NYSE: PFE), DNP Select Income Fund (NYSE: DNP), and more.

Throughout this challenging period in the market, Editor Paul McWilliams has helped his subscribers identify uniquely positioned tech sector opportunities. These include a specialty semiconductor stock that has returned 64% since McWilliams added it to the Next Inning model portfolio late last year.

By taking a free test drive of Next Inning, you'll receive real-time notification of Next Inning model portfolio buy and sell orders, the seven Next Inning Paradigm Papers covering key, long-term tech trends, and the exclusive "2009 Guide to Undervalued Tech Stocks." These reports cover nearly 100 technology companies and are chock full of charts and ratings that identify potential big winners for 2009 and which stocks investors should avoid. To accept this offer, visit the following link:

https://www.nextinning.com/subscribe/index.php?refer=prn790

The Black-Scholes model doesn't take into account intrinsic value when valuing options, only volatility and time. In a high volatility environment, there is often an opportunity to "harvest" a premium by writing options in high quality stable companies with limited downside risk to intrinsic value. Next Inning has applied this approach to the technology sector in the past with success, has recently identified several new ideas, and will publish a several more taking advantage of these anomalies.

McWilliams also looks at these topics:

-- Why does McWilliams think the price of DNP is artificially depressed? Does he think the 12%+ dividend is safe?

-- How can investors lock in returns greater than 20% with Pfizer and, at the same time, drop their risk exposure below what it would be if they just held the stock?

-- What strategy can investors use to lock in a 28% return with a very low risk exposure in the Tech sector?

-- Why does McWilliams think Analog Devices is destined to beat its guidance this quarter? How can investors lock in a 41% total return with Analog Devices, yet expose themselves to less risk than a typical Analog Devices shareholder?

Founded in September 2002, Next Inning's model portfolio has returned 118% since its inception versus 5% for the Nasdaq.

About Next Inning:

Next Inning is a subscription financial newsletter focused on technology stocks. Editor Paul McWilliams is a 20+-year semiconductor industry veteran.

NOTE: This release was published by Indie Research Advisors, LLC, a registered investment advisor with CRD #131926. Interested parties may visit adviserinfo.sec.gov for additional information. Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.

CONTACT: Marcia Martin Next Inning Technology Research, +1-888-278-5515


'/>"/>
SOURCE Indie Research Advisors, LLC
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Olympic Gold Winning Supplement Lands in the US
2. Award Winning Photographer and Museum Founder to Donate Iconic Images In Support of the Innocence Project
3. Inspired Cancer Survivor Launches Customized Hair Replacement Techniques at Award-Winning Hair Salon
4. MidMichigan Health Cuts Out Trans Fats Beginning March 1
5. Disability Community Humble Beginnings Lead to Great Things at Disabled World
6. Governor Crist Proclaims Tobacco Free Florida Week Beginning February 27
7. Icagen Board Beginning to Follow Xmark Direction
8. A Newly Approved CMS Medicare Package Expands Reimbursement Coverage for Telehealth Originating Sites Beginning January 1, 2009
9. Pennsylvania to Offer Free Nicotine Replacement Therapy Kits Beginning Feb. 2
10. Author Shares Nine Resolutions for 2009 to Create a Winning Corporate Culture
11. Cadient Group Expands Award-Winning Capabilities with Key New Hires
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... As health professionals work to improve their approach ... patient is doing more than filling out a survey; in many cases health professionals ... emphasis in health care and research on the importance of active engagement with patients ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... ‘17, and Jennifer Huggins, PharmD ’17, along with clinical associate professor Janice ... of cardiovascular diseases during the 15th Annual Women’s Health Conference. The SIU ...
(Date:10/13/2017)... ... , ... Ellevate Network, the leading network for professional women, brought together some ... at their inaugural Summit in New York City in June. The event was livestreamed ... over 3 million. To watch the Mobilize Women video, click here . ...
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the Mountains to ... to save lost souls in the Philippines. “The Journey: From the Mountains to the ... teacher of the Bible. She has taught all ages and currently teaches a class ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company has developed ... consumer and regulatory authorities worldwide. From Children’s to Adults 50+, every formula has ... highest standard. , These products are also: Gluten Free, Non-GMO, Vegan, Soy ...
Breaking Medicine News(10 mins):
(Date:9/27/2017)... and NEW YORK , Sept. 27, 2017 ... mobile health and big data solutions, today announced that its MyDario product ... check your local TV listings for when The Dr. Oz Show airs ... The ... this month. ...
(Date:9/23/2017)... -- Janssen Biotech, Inc. (Janssen) announced today that it ... Food and Drug Administration (FDA) for the Biologics License ... of moderately to severely active rheumatoid arthritis (RA). The ... to further evaluate the safety of sirukumab in the ... "We are disappointed by ...
(Date:9/19/2017)... HistoSonics, Inc., a venture-backed medical device company developing a non-invasive, robotically assisted, platform therapy that ... developments today:   ... ... Tom Tefft ... Veteran medical device executive Josh Stopek , PhD, who has led R&D and ...
Breaking Medicine Technology: